Rapid advances in molecular medicine have led to pronounced new developments in experimental and clinical cardiology. In the embrace of modern molecular biology and bridging the gap between the clinical and the genomic, cardiovascular medicine has seen major strides in the understanding of the molecular mechanisms that drive disease progression. The ability to rapidly identify candidate human genes for cardiovascular diseases lends itself to the development of diverse strategies for disease treatment and management. The wide variety of gene expressions proffers excellent targets for novel therapeutics. Gene therapy is steadily increasing in viability and represents a fascinating arena of research and clinical focus.
Návaznosti
NS10206, projekt VaV
Název: Asociace polymorfismů v genech pro metaloproteinázy, jejich inhibitory, ACE a ACE2 s centrálním pulsním tlakem u kardiovaskulárních pacientů
Investor: Ministerstvo zdravotnictví ČR, Asociace polymorfismů v genech pro metaloproteinázy, jejich inhibitory, ACE, ACE2 a apelinu s centrálním pulsním tlakem u pacientů s ischemickou chorobou srdeční